Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH On Track To Meet All MDUFA V Goals

Executive Summary

CDRH is on track to meet its MDUFA V goals, seeing a steady return to pre-pandemic levels of device authorizations and submissions.

You may also be interested in...



FDA Launches Digital Health Advisory Committee

To address the growing importance of digital health, the US FDA has established a new advisory committee to make recommendations to the agency about digital health technologies.

What A Difference A Year Makes; AI Makes The A-List

The US FDA’s Center for Devices and Radiological Health has announced the guidance documents it plans to focus on in fiscal year 2024, and this time, AI devices make the cut.

‘We Need More Time‘: Medtech Groups Testify Before EPA On ETO Emissions Regulation

Medtech groups call for extended commentary and compliance periods for two new EtO regulations from the EPA. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel